

Project IT-DIAB: gen0way obtains € 1.1 million funding from OSEO and the exclusive distribution of the research models created

The Company pursues the development of its catalog of ready-to-use models and will be the exclusive distributor of the research models created by the consortium in the cardiovascular & metabolic disease field

Lyon, France - June 9th 2008,

gen0way (ALTERNEXT-NYSE:ALGEN ; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models today reports that it has obtained:

- the exclusive distribution of the animal models resulting from this Consortium in the field of the cardiovascular and metabolic diseases. This new range of mouse models will come to reinforce the ready-to-use animals catalogue that the Company has launched in 2007 for the pharmaceutical groups. The worldwide budget for the research in the field of the cardiovascular and metabolic diseases (more than \$ 5 billion per year) represents a promising market since there currently exist very little relevant models.
- a funding of €1.1 million from OSEO to fund its contribution to the IT-DIAB program.

Alexandre Fraichard, Président Directeur Général de gen0way stated: *"We are very proud to take part in this prestigious Consortium in view of the quality of its industrial and academic partners but also in view of its ambitious objective. In less than three years, we will be able to develop and market a large range of proprietary models labellized and promoted by some of the best research laboratories in the field of the cardiovascular and metabolic diseases. It deals with an essential sales argument on a significant market totally new for gen0way. These new proprietary products represent the best strategy to continue our strong growth."*

IT-DIAB is a private/public research program bringing together industrial and academic institutions dedicated to discover new diagnostic and therapeutic solutions for targeting the embryonic stages of diabetes type 2. It gathers for companies (gen0way, Genfit, Roowin et SpiBio) and seven French academic institutions.

This Consortium anticipates a global investment in R&D of € 24.9 millions of which € 13.3 millions will be funded by OSEO. In the framework, gen0way's task will be to develop genetically modified animals presenting the physiopathological mechanisms, which mirror human diabetes. Thanks to its unique "inducible" technology, they will be able to inhibit the influence of specific genes by inducing the deterioration of the corresponding ARN messengers.

À propos de genOway

genOway (ALTERNEXT-NYSE:ALGEN) is a biotechnology company dedicated to the development of genetically modified animal models aimed at enhancing the security and relevancy of in vivo research projects. Focusing its effort on the mouse and rat, genOway's expertise combined transgenic technologies such as pronuclear microinjection, Knock-out, Knock-in, Knock- down, point mutation, humanization combined with innovative patented technologies adapted to target validation, in vivo drug screening, drug efficacy and safety testing program. Collaborations with worldwide leaders (Charles River Laboratories, Invitrogen, Tet systems, etc..) enable genOway to provide its customer with a complete portfolio of products and services for all aspects of model generation and characterization. Operating in 22 countries in Europe, North America and Asia, genOway has developed more than 450 rat and mouse lines for 50 companies and 175 research institutions. Thanks to its industrialized production facilities, genOway is involved in large-scale projects with several academic centers (German National Genome Research Network, University College London, King's College London, Max Planck Institute) and with pharmaceutical companies (BayerCorp, Boehringer Ingelheim, Johnson & Johnson).

For more information consult: www.genoway.com

Contacts:

Gilles de Poncins, CFO - genOway - finances@genoway.com

Milestones – Press & Investors Relation

Bruno Arabian/Jean-Christophe Labastugue

Tel. : +33 (0)1 70 08 04 13 / 06 87 88 47 26- milestones@milestones-fr.com

Warning: This press release expressly contains, in an implicit manner, certain prospective statements concerning genOway and its activity. These statements rely on certain risks, known or unknown, uncertainty or on other factors that may lead to actual results, financial conditions, performance or achievements on the part of genOway that may differ significantly from the results, financial conditions, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to update the prospective statements contained therein, either as a result of new information, future events or other. For a description of the risks or uncertainty of a nature to cause a difference between genOway's actual results, financial conditions, performance or achievements and those contained in the prospective statements, please refer to the section on «Risk Factors» on the Prospectus available on the genOway website <http://www.genoway.com>